- Home
- DAVA vs RXST Comparison
DAVA vs RXST Comparison
Compare DAVA & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | RXST |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 305.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAVA | RXST |
|---|---|---|
| Price | $4.43 | $6.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | ★ $14.57 | $11.60 |
| AVG Volume (30 Days) | 368.8K | ★ 612.2K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.29 | $9.57 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.38 | $6.35 |
| 52 Week High | $21.69 | $27.13 |
Technical Indicators
Market Signals| Indicator | DAVA | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 28.17 |
| Support Level | $4.38 | N/A |
| Resistance Level | $5.66 | $9.11 |
| Average True Range (ATR) | 0.22 | 0.41 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 6.59 | 11.89 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.